このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effects of Supplementation on Performance in Football Players (FOOTBALL-TCP)

2026年5月21日 更新者:Krzysztof Mizera

Effects of Combined Taurine, Caffeine, and Phosphatidylserine Supplementation on Physical and Cognitive Performance in Professional Male Football Players

This study investigated the effects of short-term supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players. Eighty-one players were randomly assigned to one of three groups: placebo, taurine plus caffeine, or taurine plus caffeine combined with phosphatidylserine. Supplementation was administered for 10 days, with a final dose taken 60 minutes before a standardized 105-minute football training session.

Primary and secondary outcomes included sprint performance, reaction time, GPS-derived locomotor variables, and technical and tactical performance indicators. The aim of the study was to evaluate whether combined multi-ingredient supplementation could improve performance and attenuate fatigue-related declines under match-like conditions.

調査の概要

詳細な説明

This randomized, placebo-controlled, single-blind study evaluated the effects of combined supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players.

Eighty-one participants aged 19-32 years were randomly assigned to one of three groups: placebo (lactose), taurine plus caffeine (1500 mg taurine + 200 mg caffeine), or taurine plus caffeine plus phosphatidylserine (1500 mg taurine + 150 mg caffeine + 300 mg phosphatidylserine daily for 10 days). All participants completed a 10-day supplementation period, followed by a standardized 105-minute football training session.

Outcome measures included sprint performance (30 m sprint time), reaction time (visual and auditory), GPS-derived variables (total distance, sprint activity, speed, accelerations, and decelerations), and technical and tactical performance indicators assessed by coaching staff and video analysis.

The study was conducted under controlled environmental conditions and in accordance with standardized training procedures. Data were analyzed using analysis of variance (ANOVA) with post hoc testing. The aim was to determine whether multi-ingredient supplementation could enhance performance and reduce fatigue-related declines in a football-specific setting.

研究の種類

介入

入学 (実際)

81

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Łódżkie
      • Lodz、Łódżkie、ポーランド、94-020
        • ŁKS Łódź

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Male professional football (soccer) players
  • Age 19-32 years
  • Currently participating in regular team training (4-5 sessions per week)
  • Medically cleared for participation in high-intensity physical activity
  • Provided written informed consent

Exclusion Criteria:

  • Current injury or musculoskeletal condition affecting performance
  • Chronic disease or medical condition
  • Use of medications that may affect physical or cognitive performance
  • Regular use of dietary supplements or caffeine prior to the study period
  • Smoking or alcohol consumption
  • Failure to comply with study procedures

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Placebo
Participants received a placebo (lactose) daily for 10 days.
Placebo (lactose) administered daily for 10 days
実験的:Taurine + Caffeine
Participants received taurine (1500 mg) and caffeine (200 mg) daily for 10 days.
Taurine 1500 mg and caffeine 200 mg administered daily for 10 days
実験的:Taurine + Caffeine + PS
Participants received taurine (1500 mg), caffeine (150 mg), and phosphatidylserine (300 mg) daily for 10 days.
Taurine 1500 mg, caffeine 150 mg, and phosphatidylserine 300 mg administered daily for 10 days

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
30 m sprint time (seconds)
時間枠:Day 10 (final training session following supplementation)
Time to complete a 30 meter sprint under standardized conditions, expressed in seconds; calculated as the mean of valid trials.
Day 10 (final training session following supplementation)

二次結果の測定

結果測定
メジャーの説明
時間枠
Reaction time (visual and auditory)
時間枠:Day 10 (post-supplementation)
Visual and auditory reaction time measured using standardized computerized reaction time tests (e.g., validated software-based assessment tools), expressed as mean response time in seconds across valid trials.
Day 10 (post-supplementation)
Total distance (meters)
時間枠:Day 10 (during standardized training session)
Total distance covered during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters.
Day 10 (during standardized training session)
Running speed (m/s)
時間枠:Day 10 (during standardized training session)
Mean running speed during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters per second.
Day 10 (during standardized training session)
Sprint count (number)
時間枠:Day 10 (during standardized training session)
Total number of sprint efforts recorded during the standardized training session using GPS tracking devices.
Day 10 (during standardized training session)
High-speed running distance (meters)
時間枠:Day 10 (during standardized training session)
Distance covered at high-speed running thresholds during the standardized training session, measured using GPS tracking and expressed in meters.
Day 10 (during standardized training session)

その他の成果指標

結果測定
メジャーの説明
時間枠
Sprint time decline (%)
時間枠:Day 10 (during final training session; comparison between first and second halves)
Percentage decline in 30 m sprint time between the first and second halves of the standardized training session, measured using electronic timing gates and expressed as percentage change.
Day 10 (during final training session; comparison between first and second halves)
Running speed decline (%)
時間枠:Day 10 (during final training session; comparison between first and second halves)
Percentage decline in running speed between the first and second halves of the standardized training session, measured using GPS tracking devices and expressed as percentage change.
Day 10 (during final training session; comparison between first and second halves)
Passing accuracy (%)
時間枠:Day 10 (during standardized training session)
Percentage of successful passes during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
Day 10 (during standardized training session)
Dribbling success (%)
時間枠:Day 10 (during standardized training session)
Percentage of successful dribbling attempts during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
Day 10 (during standardized training session)
Ball recoveries (number)
時間枠:Day 10 (during standardized training session)
Total number of ball recoveries performed during the standardized training session, assessed using video-based performance analysis and expressed as a count.
Day 10 (during standardized training session)
Tactical performance score (units)
時間枠:Day 10 (during standardized training session)
Coach-rated tactical performance during the standardized training session, including positioning, decision-making, and support play, assessed using a standardized rating scale and expressed in standardized score units.
Day 10 (during standardized training session)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Krzysztof Maciej MIZERA, PhD、1. Vizja University in Warsaw, Faculty of Medical Sciences and Health Sciences, 01-143 Warsaw, Poland

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月25日

一次修了 (実際)

2025年4月5日

研究の完了 (実際)

2025年4月5日

試験登録日

最初に提出

2026年4月28日

QC基準を満たした最初の提出物

2026年5月5日

最初の投稿 (実際)

2026年5月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月26日

QC基準を満たした最後の更新が送信されました

2026年5月21日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly available due to confidentiality restrictions related to professional athletes. Data may be available from the corresponding author upon reasonable request.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する